Attitudes to directly observed antiretroviral treatment in a workplace HIV care programme in South Africa

Sexually Transmitted Infections

Volumn 83, Issue 5, 2007, Pages 383-386

  Page Shipp, Liesl S ^a,b   Charalambous, Salome ^c   Roux, Surita ^c   Dias, Belinda ^d   Sefuti, Clement ^c   Churchyard, Gavin J ^e   Grant, Alison D ^f  

^a Aragon Consulting   (South Africa)

^b AngloGold Ashanti Limited   (South Africa)

^c AURUM INSTITUTE   (South Africa)

^d CSIR Natural Resources and the Environment   (South Africa)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG SELF ADMINISTRATION; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUALITY; SOUTH AFRICA;

ADULT; ANTI-HIV AGENTS; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDIES; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; SOUTH AFRICA; WORKPLACE;

EID: 34547795272     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2007.025585     Document Type: Article

References (20)

1. Roux S, Fielding KL, Day JH, et al. Risk factors for HIV prevalence and incidence among mineworkers in South Africa: a potential setting for HIV vaccine trials. XV International AIDS Conference, Bangkok, July 2004 (abstract MoPeC3485).
2. Charalambous S, Grant AD, Day JH, et al. Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 2007;19:34-41.
3. Charalambous S, Innes C, Muirhead D, et al. Evaluation of a workplace HIV treatment programme in South Africa. AIDS 2007. In press.
4. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001;33:865-72.
5. Farmer P, Leadre F, Mukherjee J, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001;358:404-9.
6. Mitty JA, Stone VE, Sands M, et al. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002;34:984-90.
7. World Health Organization. The stop TB strategy. Building on and enhancing DOTS to meet the TB-related Millenium Development Goals, WHO/HTM/STB/2006.37.Geneva, WHO, 2006.
8. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-9.
9. Kenyon TA, Mwasekaga R, Huebner, et al. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999;3:4-11.
10. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999;3:457-65.
11. Mukherjee JS, Ivers L, Leandre F, et al. Antiretroviral therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr 2006;43:S123-6.
12. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infecf Dis 2006;42:1628-35.
13. Stenzel MS, McKenzie M, Mitty JA, et al. Enhancing adherence to HAART: a pilot program of modified directly observed therapy. AIDS Read 2001;11:324-8.
14. Kirkland LR, Margaret AF, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naïve incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis 2002;34:511-8.
15. Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006;4:S127-33.
16. Macalino GE, Mitty JA, Bazerman LB, et al. Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learnt from a pilot study. Clin Infect Dis 2004;38(Suppl. 5):S393-7.
17. Tuldra A, Wu A. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002;15:154-7.
18. Sigxashe TA, Baggaley R, Matthews C. Attitudes to disclosure of HIV status to sexual partners. S Afr Med J 2001;91:908-9.
19. Klitzman RL, Kirshenbaum SB, Dodge B, et al. Intricacies and inter-relationships between HIV disclosure and HAART: a qualitative study. AIDS Care 2004;16:628-40.
20. Kilewo C, Massawe A, Lyamuya E, et al. HIV counseling and testing of pregnant women in sub-Saharan Africa: experiences from a study on prevention of mother-to-child HIV-1 transmission in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2001;15:458-62.